Company intelligence / Profile preview

BIMINI Biotech

Ownership: Private
Development stage: Preclinical

Overview

The company has a proprietary WASp agonist (BM-011) that is currently in the pre-clinical stage and is demonstrating potent activity in various lymphomas. Their compounds show strong synergism with FDA-approved drugs in hematological cancers and are active in resistant cell lines.

Therapeutic areas: OncologyHematology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

6 assets

BM001

Preclinical

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on BIMINI Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIMINI Biotech.

Explore the full profile